Real world evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)

Study identifier:D3250R00101

ClinicalTrials.gov identifier:NCT05271526

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A multicenter, single arm, non-interventional, observational, prospective study to assess demographic characteristics, burden of disease and short-term patient reported outcomes on symptom relief in severe eosinophilic asthma patients aged older than 18 qualifying for treatment with benralizumab in Russia

Medical condition

Severe Eosinophilic Asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

3

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 16 May 2022
Estimated Primary Completion Date: 30 Nov 2023
Estimated Study Completion Date: 30 Nov 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria